Inadequate Initial Response is the Top Reason Why Rheumatologists Move Patients from Simponi and Cimzia, According to a New Report from Decision Resources BURLINGTON, Mass., Dec. 7, 2010 /PRNewswire/ ...
EXTON, Pa.--(BUSINESS WIRE)--BioTrends Research Group, one of the world’s leading research and advisory firms for specialized biopharmaceutical issues, finds that there has been a slight increase in ...
Humira Leads Remicade in the Treatment Algorithm for Psoriatic Arthritis Despite Launching Around the Same Time, According to New Analysis from Decision Resources BURLINGTON, Mass.--(BUSINESS WIRE)-- ...
Every time Charlotte publishes a story, you’ll get an alert straight to your inbox! Enter your email By clicking “Sign up”, you agree to receive emails from ...
Alberta, Canada becomes the latest province to begin switching patients from originator adalimumab (Humira) to biosimilar versions as part of its Biosimilars Initiative. Alberta, Canada has expanded ...
What you should know about the safety and side effects of biologic drugs for psoriasis and arthritis
Biologic drugs that treat various autoimmune disorders have seen substantial increases in prescriptions over the last 20 years. The drugs are effective in treating rheumatoid arthritis, psoriasis and ...
A report predicting that Humira will become the world’s biggest product in two years’ time generated positive news for the Abbott Labs/Eisai arthritis drug. Several factors are driving the bullish ...
An icon in the shape of a lightning bolt. Impact Link A new therapeutic treatment might be making its way to the anti-aging market, and it could stand to disrupt multibillion-dollar franchises like ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback